Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy

Table 1 Baseline characteristics of triglyceride glucose index < 1.79 and triglyceride glucose index ≥ 1.79, n (%)

Variables	Overall (n = 300)	Low TyG index (n = 164)	High TyG index (n = 136)	P value
BMI, kg/m2, mean ± SD	22.71 ± 2.93	22.12 ± 2.86	23.42 ± 2.86	< 0.001a
Fasting glucose, mg/dL, mean ± SD	6.53 ± 1.77	5.20 ± 1.02	8.13 ± 0.99	< 0.001a
Fasting triglycerides, mg/dL, mean ± SD	1.74 ± 0.41	1.45 ± 0.27	2.09 ± 0.23	< 0.001a
Tyg index, mean ± SD	1.67 ± 0.54	1.29 ± 0.43	2.12 ± 0.22	< 0.001a
Age, years				0.514
< 60	135 (45.00)	71 (43.29)	64 (47.06)
≥ 60	165 (55.00)	93 (56.71)	72 (52.94)
Sex				0.833
Female	152 (50.67)	84 (51.22)	68 (50.00)
Male	148 (49.33)	80 (48.78)	68 (50.00)
Drinking history				0.387
No	204 (68.00)	115 (64.02)	89 (65.44)
Yes	92 (32.00)	49 (29.88)	47 (34.56)
Smoking history				0.859
No	208 (69.33)	113 (68.90)	95 (69.85)
Yes	92 (30.67)	51 (31.10)	41 (30.15)
ECOG				0.583
0	198 (66.00)	106 (64.63)	92 (67.65)
1	102 (34.00)	58 (35.37)	44 (32.35)
Site				0.054
Stomach	150 (50.17)	74 (45.12)	64 (47.06)
Gastric and esophageal binding	149 (49.83)	90 (54.88)	72 (52.94)
Histological				0.189
Adenocarcinoma	216 (72.00)	113 (68.90)	103 (75.74)
Other	84 (28.00)	51 (31.10)	33 (24.26)
CEA, ng/mL				0.188
< 3	90 (30.00)	44 (26.81)	46 (33.82)
≥ 3	210 (72.00)	120 (73.17)	90 (66.18)
AFP, ng/mL				0.169
< 15	253 (84.33)	134 (81.71)	119 (87.50)
≥ 15	47 (15.67)	30 (18.29)	17 (12.50)
CA-199, ng/mL				0.071
< 37	184 (61.33)	93 (56.71)	91 (66.91)
≥ 37	116 (38.67)	71 (43.29)	45 (33.09)
Liver metastasis				0.798
No	194 (64.67)	105 (70.12)	89 (65.44)
Yes	106 (35.33)	59 (35.98)	47 (34.56)
Peritoneal metastasis				0.423
No	241 (80.33)	129 (78.66)	112 (82.35)
Yes	59 (19.67)	35 (21.34)	24 (17.65)
EBV status				0.390
No-infect	253 (84.33)	141 (85.98)	112 (82.35)
Infect	47 (15.67)	23 (14.02)	24 (17.65)
PD-L1 expression				0.059
CPS < 5	51 (17.00)	34 (20.73)	17 (12.50)
CPS ≥ 5	249 (83.00)	130 (79.27)	119 (87.50)
MMR status				0.125
pMMR	289 (96.33)	155 (94.51)	134 (98.53)
dMMR	11 (3.67)	9 (5.49)	2 (1.47)

^aP < 0.05.

TyG: Triglyceride glucose; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic-antigen; AFP: Alpha-fetoprotein: CA-199: Carbohydrate antigen 199; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.